Ameriserv Financial 2025 10-K: Total interest $71.35M, EPS $0.34

AMERISERV FINANCIAL INC /PA/ (ASRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 asrv-20260721xex99d1.htm EX-99.1 Exhibit 99.1 AMERISERV FINANCIAL REPORTS INCREASED EARNINGS FOR THE SECOND QUARTER AND FIRST SIX MONTHS OF 2026 AND ANNOUNCES QUARTERLY COMMON STOCK CASH DIVIDEND ​ JOHNSTOWN, PA - AmeriServ Financial, Inc. (NASDAQ: ASRV) reported second

Jaguar Land Rover (JLR), owned by Tata Motors, is in talks with NATO countries to sell its Defender military vehicle. JLR is also bidding for a £900m UK defense contract and has set up a new defense division to explore global partnerships. The company is expanding into the defense sector amid weaker demand and higher costs elsewhere. JLR is not linking this move to its planned 4,000 job cuts. The new Defender Wolf Series II was unveiled, designed for military use. JLR also aims to enter the $80b

Lockheed Martin awarded L3Harris Technologies a $4.7b contract over seven years for PAC-3 MSE rocket motors. The deal supports L3Harris' propulsion segment and ties into new manufacturing facilities in Camden, Arkansas, expected to open in 2027. Analysts project $28.0b revenue and $3.0b earnings by 2029, with a 38% potential upside. Risks include margin management, debt, and U.S. budget decisions.

Combined BHP Ports Unions will seek arbitration with BHP over a wage deal dispute for Port Hedland iron ore operations. The union, representing 450 workers, seeks a four-year agreement, while BHP offered a 17% pay increase and A$25,000 transition payment. The union claims 40% of workers would be worse off under BHP's proposal.

Sempra Infrastructure signed a 20-year LNG supply deal with Petrobras for 800,000 tonnes per year, sourced from its Port Arthur LNG Phase 2 project in Texas. The agreement adds Petrobras as Sempra's first South American LNG customer. Port Arthur Phase 2, with a $14 billion estimated cost, is set to add 13 million tonnes per annum of liquefaction capacity and begin operations in 2030-2031. Sempra has previously secured LNG agreements with ConocoPhillips, JERA, and EQT for Phase 2.

Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed in Phase 3 trials, testing different cardiovascular risk theories. Both drugs did not reduce cardiovascular events despite lowering targets. Novartis reported pelacarsen's Lp(a)HORIZON trial results, while Novo Nordisk halted ziltivekimab's HERMES and ATHENA trials. Analysts estimated pelacarsen's peak sales at $4B-$6B. Both companies have other trials ongoing.